Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system to maximize viral clearance.
Influenza (“the flu”) is a contagious viral infection that can cause mild to severe illness, sometimes resulting in death. While today’s flu vaccines are credited with significant public health benefits and offer our current best defense, only 49% of Americans get an annual flu vaccine1, and a majority of those people do not respond. As a result, most Americans are still at risk of getting the flu yearly. In fact, during the 2018-19 flu season, a staggering 71% did not respond to vaccination and 34,200 people died of flu-related illness in the US alone. The estimated average annual total economic burden of influenza to the healthcare system and society is more than $11.2 billion. For more information about influenza, visit the CDC website.
ANTIVIRAL CONJUGATES (AVCs) FOR INFLUENZA PREVENTION: CD377
Currently, the only preventative measure against influenza is the seasonal flu vaccine. While it is critical to global health, the vaccine has significant limitations including:
The vaccine must be redesigned every year based on a prediction for the next season’s dominant circulating strains
The vaccine is significantly less effective in immune-compromised individuals and the elderly
Protection doesn’t begin until 14 days after vaccination
Cidara is developing its lead flu candidate, CD377, to achieve universal prevention of seasonal and pandemic influenza with a single dose. As an antiviral conjugate (AVC), CD377 is not a vaccine or a monoclonal antibody. Its targeting domains are small molecule antivirals that bind to a highly conserved target on the influenza cell surface, which is essential for viral proliferation and enables universal influenza coverage. CD377 has the potential to offer significant advantages over the current flu vaccine:
• True universal protection, against all influenza strains and for all people, including those with a compromised immune system
• Near-immediate protective effects
Cidara is currently conducting IND-enabling studies for CD377 for influenza prevention in order to begin Phase 1 clinical trials. Preclinical studies with CD377 demonstrate:
ANTIVIRAL CONJUGATES (AVCs) FOR INFLUENZA TREATMENT: CD377
There are currently four drugs recommended by the CDC for treating influenza. All have one or more of the following limitations:
Short half-life and limited efficacy window
Susceptibility to resistance
Limited routes of administration
Cidara’s lead AVC candidate for flu treatment, CD377, is designed to disrupt the current standard of care. CD377’s targeting domains are small molecule antivirals that bind to a highly conserved target on the cell surface of all influenza viral strains which is essential for viral proliferation. With this mechanism, CD377 has the potential for universal coverage of influenza A and B, as well as all major clinically characterized drug-resistant strains.
Cidara is currently conducting studies in support of an investigational new drug application for CD377. Preclinical treatment studies with CD377 demonstrate: